Welcome to our dedicated page for Fibrobiologics SEC filings (Ticker: FBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.
The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.
FibroBiologics, Inc. entered into a private placement that provides $3,000,000 in gross proceeds through pre-funded warrants and common stock priced at $0.735 per share. Net proceeds are approximately $2.6 million after fees and expenses, and the company plans to use the cash for working capital and general corporate purposes.
The investor received 4,081,633 shares of common stock or pre-funded warrants plus 4,081,633 short-term warrants and 4,081,633 long-term warrants, each with a $0.735 exercise price. If these warrants are fully exercised for cash after stockholder approval, FibroBiologics could receive about $6.0 million in additional gross proceeds. The transaction also includes 285,714 placement agent warrants at a $0.9188 exercise price and is being conducted under Securities Act exemptions with related resale registration rights.
FibroBiologics, Inc. director Robert E. Hoffman reported receiving a grant of stock options. He was awarded stock options covering 30,803 shares of common stock at an exercise price of $0.7503 per share, expiring on June 22, 2036. These options will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting. Following this compensation-related grant, Hoffman holds 30,803 stock options directly.
FibroBiologics, Inc. director Richard C. Cilento Jr. reported a grant of stock options. He received options to acquire 30,803 shares of common stock at an exercise price of $0.7503 per share. The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting and expire on June 22, 2036.
FibroBiologics, Inc. director Matthew Link received a grant of stock options covering 30,803 shares of common stock. The options have an exercise price of $0.7503 per share and expire on June 22, 2036. Following this grant, he holds options for 30,803 shares directly. The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting.
FibroBiologics, Inc. director Niklas Victoria Ninon Olivia received a grant of 30,803 stock options to buy common stock at an exercise price of $0.7503 per share. The options vest in full on the earlier of the first anniversary of grant or the next annual meeting and expire on June 22, 2036. Following this award, Olivia directly holds 30,803 options.
FibroBiologics, Inc. reported results of its June 22, 2026 annual meeting, where stockholders approved the new 2026 Equity and Incentive Compensation Plan, succeeding the 2022 Stock Plan. As of June 22, 2026, 2,061,968 shares of common stock are available for awards under the plan, including 2,000,000 newly approved shares.
The plan includes an evergreen feature that can add up to 4% of outstanding shares each fiscal year from 2027 through 2036, and caps incentive stock option issuances at 2,000,000 shares and non‑employee director compensation at $800,000 per year. Stockholders also approved, for Nasdaq Listing Rule 5635(d) purposes, the issuance of up to 2,272,728 shares upon exercise of warrants issued under March 31, 2026 Securities Purchase Agreements and up to 159,091 shares upon exercise of warrants issued under an Engagement Letter with H.C. Wainwright & Co., LLC.
Pete O’Heeron was elected as a Class III director, the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for 2026 was ratified, and the 2026 plan itself was approved by separate vote. Shares representing 4,174,791 votes were present out of 6,833,915 entitled to vote as of the record date.
FibroBiologics, Inc. has updated its existing at-the-market stock offering program with H.C. Wainwright & Co. Under a new prospectus supplement filed on May 5, 2026, the company may sell shares of common stock for an aggregate offering price of up to $7,500,000 under this ATM facility.
The ATM sales are made pursuant to FibroBiologics’ shelf registration statement on Form S-3, declared effective by the SEC on February 10, 2025, and related prospectus supplements. To date, 71,830 shares have been sold under the Sales Agreement. The company also filed its counsel’s legal opinion and consent covering the validity of the shares issuable under the program.
FibroBiologics filed a prospectus supplement updating its at‑the‑market sales capacity under the Form S-3 registration: it may sell up to $7,500,000 of Common Stock from time to time through H.C. Wainwright & Co. The supplement states the company sold approximately $8.14 million of Common Stock in the prior 12 months and sold about $0.17 million under the earlier supplement. The company reports a public float of approximately $47.0 million based on 5,399,112 shares held by non‑affiliates as of May 5, 2026, and notes Nasdaq closing prices of $1.38 (May 4, 2026) and $8.70 (March 6, 2026) used in float calculation. The offering is subject to the Form S-3 General Instruction I.B.6 limitations and the Sales Agreement, with any additional sales requiring a new prospectus supplement.
FibroBiologics, Inc. reported new stock option grants to its senior leadership under the company’s 2022 Stock Plan. On May 4, 2026, the Compensation Committee granted options to purchase 92,410 shares of common stock to Chief Executive Officer Pete O’Heeron at an exercise price of $1.38 per share.
Each of Chief Financial Officer Jason D. Davis, Chief Scientific Officer Hamid Khoja, Ph.D., and General Counsel Ruben A. Garcia received options to purchase 61,607 shares, also at $1.38 per share. One quarter of each grant vests on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments for executives who remain in continuous service.